Insulet Corporation (PODD)

NASDAQ
Currency in USD
279.55
-4.71(-1.66%)
Closed
After Hours
279.550.00(0.00%)
PODD Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Earnings results expected in 7 days
Fair Value
Day's Range
278.94282.92
52 wk Range
160.19289.46
Key Statistics
Edit
Prev. Close
284.26
Open
280.22
Day's Range
278.94-282.92
52 wk Range
160.19-289.46
Volume
443.97K
Average Vol. (3m)
541.14K
1-Year Change
47.97%
Book Value / Share
15.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
292.29
Upside
+4.56%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Insulet Corporation Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation SWOT Analysis


Competitive Landscape
Analyst price targets range from $200 to $236, reflecting optimism amid potential challenges from new market entrants expected by late 2025
Financial Momentum
Delve into Insulet's robust financial performance, with Q3 2024 sales of $543.9 million exceeding estimates and EPS beating consensus by 13 cents
Market Expansion
Explore Insulet's entry into the vast, underpenetrated Type 2 diabetes market, potentially reaching 6 million new patients in the United States alone
Tubeless Innovation
Insulet's Omnipod 5, now FDA-cleared for both Type 1 and Type 2 diabetes, positions the company as a leader in automated insulin delivery systems
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q3/2024

  • Insulet surpassed $2B in full-year revenue; Omnipod revenue up 26% (23% US, 35% international)
  • FDA cleared Omnipod 5 for type 2 diabetes; company expanding sales force to target this market
  • Raised full-year guidance: total Omnipod growth 21-22%; Q4 revenue growth projected 13-16%
  • Strong financials: 69.3% gross margin, 16.2% operating margin, $900M cash on hand
  • Aims to capture 40%+ of insulin-intensive market by 2025; optimistic about type 2 diabetes demand
Last Updated: 11/08/2024, 02:02 PM
Read Full Transcript

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
47.4x−3.9x−0.6x
PEG Ratio
0.200.020.00
Price / Book
17.8x1.3x2.6x
Price / LTM Sales
10.1x2.8x3.1x
Upside (Analyst Target)
5.5%88.5%52.8%
Fair Value Upside
Unlock15.7%8.4%Unlock

Analyst Ratings

19 Buy
4 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 292.29
(+4.56% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
0.90 / 0.78
Revenue / Forecast
543.90M / 518.76M
EPS Revisions
Last 90 days

People Also Watch

166.61
VST
-0.60%
85.13
TPR
+4.63%
699.46
MPWR
+0.06%
665.08
AXON
-0.62%
385.66
ELV
-1.42%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 279.55

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 19.67B.

What is Insulet Earnings Per Share?

The Insulet EPS is 6.01.

What Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Feb 20, 2025.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.